Antiapoptotic and mutant oncoproteins represent another promising area, with Bcl‐xL degraders limiting platelet toxicity by selectively targeting tumor cells [285], and KRAS^G12C and G12D degraders addressing both catalytic and scaffolding functions [286, 287, 288]. Here, BCL2L1 is linked to neoplasm.